Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous vs. Intravenous Daratumumab in Relapsed or Refractory Multiple Myeloma
NCT03277105Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2017
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall Response Rate and Maximum Trough Concentration. Started Oct 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03277105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277105.